Notably, treatment with investigational anticancer agents such as AICAR, an AMPK activator, and PI-103, a dual PI3K/mTOR inhibitor, was shown to restore GSTM5 expression and increase treatment sensitivity in resistant ovarian cancer cells [38]. The gene discussed is MTOR; the disease is ovarian cancer.